NCT04958954View on ClinicalTrials.gov

Post-Marketing Safety Study of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA-1273 COVID-19 Vaccine in the United States

CompletedOBSERVATIONAL
Enrollment

50,000,000

Participants

Timeline

Start Date

July 7, 2021

Primary Completion Date

August 31, 2022

Study Completion Date

June 30, 2023

Conditions
SARS-CoV-2
Trial Locations (1)

10001

Aetion Inc., New York

All Listed Sponsors
lead

ModernaTX, Inc.

INDUSTRY